Effects of extended-release niacin with laropiprant in high-risk patients. - Wikidata - awgldk - TriplyDB

Effects of extended-release niacin with laropiprant in high-risk patients.

Effects of extended-release niacin with laropiprant in high-risk patients.

http://www.wikidata.org/entity/Q35205560

about

Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies High density lipoprotein and metabolic disease: Potential benefits of restoring its functional properties Hypertriglyceridemia and Cardiovascular Diseases: Revisited Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens.Familial hypercholesterolemia: Review of diagnosis, screening, and treatment Low High-Density Lipoprotein and Risk of Myocardial Infarction HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis The role of the lymphatic system in cholesterol transport PCSK9 inhibition: the way forward in the treatment of dyslipidemia Vitamin paradox in obesity: Deficiency or excess?Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?Current therapies for lowering lipoprotein (a)Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients China Patient-centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction: Study Design.Glycaemic Effects of Non-statin Lipid-Lowering Therapies Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders New Era of Lipid-Lowering Drugs Statin-Associated Muscle Adverse Events: Update for clinicians Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council Low-normal thyroid function and novel cardiometabolic biomarkers Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations The Role of Emerging Risk Factors in Cardiovascular Outcomes Hypertriglyceridemia: the importance of identifying patients at risk.HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation.Meta-analysis of genome-wide association studies of HDL cholesterol response to statins.Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.Mendelian randomization analysis of a time-varying exposure for binary disease outcomes using functional data analysis methods.Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients.Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitm Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia.Association between High-density-lipoprotein-cholesterol Levels and the Prevalence of Asymptomatic Intracranial Arterial Stenosis.The first Late Triassic Chinese triadophlebiomorphan (Insecta: Odonatoptera): biogeographic implications.Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects.

P2860

Q26738588-6EBCFF8A-843D-4E05-956B-9ABE64E66DF9 Q26750603-044CA757-FFCC-48CB-9BC4-8E7D403229B7 Q26750954-D03E9CDD-8405-4452-AFDA-0165D1952003 Q26765137-FCE95DC3-4018-40B1-BEE3-0932E0C401A3 Q26765157-A7DE3040-3646-436C-9586-3606797C150F Q26766157-4FDA43D9-FEE2-46A0-A495-1BFA89D00D20 Q26770143-69C650EC-3179-42D9-9088-C2DA55DD629E Q26773899-2995BC5C-EB3F-4100-A25A-98ED04279168 Q26782972-1553BB72-C741-4992-8F01-C1E251CB43EC Q26782973-557C3DAD-015D-4918-B8B3-64B401D0DD32 Q26784482-FC675FA2-B5A8-498A-B93E-05BE049BBAE0 Q26795769-98BB1D29-A61D-4E3F-9808-E0040553783D Q26799534-53BBFF8E-3118-4069-9C35-1F7E24826799 Q26830297-43D4AD7A-675F-4BB7-A670-09E1E779D290 Q27006968-A2559DDF-E404-4090-B1FE-26E1E9F137C4 Q27302208-073A4B2B-5AA9-4C99-B388-E6D7DD62C256 Q28070152-8A6553B5-913A-4C79-B87C-C5591D4B834A Q28070296-02443072-BB23-4DFF-84B7-0AB1A596B02F Q28072298-637D5D11-BB7D-473E-B984-98E3AA846544 Q28074144-7A7FB9B9-C3CE-4E23-9C36-D079696D09BC Q28079294-5C66055F-7B50-4C4B-898E-9889739E4ED7 Q28084156-6BB09713-26C2-4069-BDCF-8CB9E9BED9B3 Q28084990-074D179E-CF8A-43D3-B488-563DA2BFC026 Q28086787-718795E9-94BB-4819-99E6-9FAB4F138A00 Q29994487-B2F47D3B-B6E1-4EBE-BC6B-5F475DACE1D8 Q30234550-DBD99F30-5847-4393-9883-CA12539CCA9B Q30244825-B3B49042-8B92-4B16-AFA8-C3C5AF2E8079 Q30251918-7D2981CC-E9E9-4197-A3FA-BE9D6EB7783A Q30276013-6A5D6E64-69D7-418F-A039-55DABA6709AF Q30364133-FEBCCD32-A598-4E37-8CBF-4081653D89CD Q31140917-F599D61A-F701-4D1D-8CA5-F1F2285FE73B Q33432308-EFDAEE26-E563-46CC-8D2C-659600A8CBDE Q33572720-6D342314-6589-42C7-BA01-8E5FFA2C9617 Q33578422-83FF3032-D005-4C3C-86C4-63517E874ADE Q33623532-8201C79B-F047-479E-8147-DFACEA2F6E35 Q33643426-E98F164E-50A6-45C5-9D9F-131499C8D0DE Q33646780-8B936440-8F64-4A2E-A2D0-BA7ABCDF65FA Q33673735-9D45EA62-E5C5-4A44-9541-ADCE427976BD Q33683980-68D9A2F0-DDAE-482A-A4E5-C48CFEFD7CAD Q33831184-91D8CFD1-71CF-449B-8342-8E12D12C350D

P2860

Effects of extended-release niacin with laropiprant in high-risk patients.

http://www.wikidata.org/entity/Q35205560

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Effects of extended-release niacin with laropiprant in high-risk patients.

@ast

Effects of extended-release niacin with laropiprant in high-risk patients.

@en

type

label

Effects of extended-release niacin with laropiprant in high-risk patients.

@ast

Effects of extended-release niacin with laropiprant in high-risk patients.

@en

prefLabel

Effects of extended-release niacin with laropiprant in high-risk patients.

@ast

Effects of extended-release niacin with laropiprant in high-risk patients.

@en

P1433

Q35205560-B7BE119A-1BC1-4513-8A72-42F16AEAE8BA

P1476

Q35205560-02080148-D827-43D8-9B2D-AADED05366B7

P2093

Q35205560-05BCBD8F-3E00-4867-A627-5EA6FC38C3E2

Q35205560-0AD0A91A-AD14-4207-878D-D427E498EEE3

Q35205560-44601BB5-837A-4463-A003-6C3B3B4ACE18

Q35205560-7EBF289D-9409-4496-8510-377EBBAEBE18

Q35205560-8D1E1839-EEB7-4932-9A15-B4E757D9670B

Q35205560-A496E7E5-1C1A-4A3C-87C0-B6BA2F9AA761

Q35205560-D0BA4A5F-ED1F-48C9-A603-FC2C0B7FCF4B

P304

Q35205560-24568FF9-7189-480E-A105-D051E779FFA8

P31

Q35205560-580D68F5-C6F6-4494-897B-E38871A0540B

P356

Q35205560-3AA763ED-80A0-4013-A056-A428DC5FCD9C

P407

Q35205560-604E9483-9837-4EB6-9A6B-229BFB1038C8

P433

Q35205560-44706428-C3C5-4E70-A38B-1B5DD41CA284

P478

Q35205560-89179AD4-81BD-41A4-9937-65F20CBBF4C1

P50

Q35205560-5AE8744D-40C0-48ED-A4C0-54AE5F7283C0

Q35205560-A466C145-158B-4545-9B5B-DD7DE694FFAD

Q35205560-C9567633-7821-4714-9AE9-887C58B54F0E

Q35205560-F69DFDCF-8138-4C27-A29E-45C798493F2D

Q35205560-F7239E17-674B-4DF7-AB3E-6912187E0315

P577

Q35205560-128F16C5-A5A2-467A-8C13-58BF04438E42

P5875

Q35205560-D603BF26-AA15-49CC-A78F-AD5389D736BC

P698

Q35205560-DBE33EC2-F077-43EF-996C-CD1A95B18C8D

P356

P1433

The New England Journal of Medicine

P1476

Effects of extended-release niacin with laropiprant in high-risk patients.

@en

P2093

HPS2-THRIVE Collaborative Group

http://www.w3.org/2001/XMLSchema#string

Jane Armitage

http://www.w3.org/2001/XMLSchema#string

Jemma C Hopewell

http://www.w3.org/2001/XMLSchema#string

Joseph Tomson

http://www.w3.org/2001/XMLSchema#string

Lixin Jiang

http://www.w3.org/2001/XMLSchema#string

Rory Collins

http://www.w3.org/2001/XMLSchema#string

Theingi Aung

http://www.w3.org/2001/XMLSchema#string

P304

203-212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1300955

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

371

http://www.w3.org/2001/XMLSchema#string

P50

Karl Wallendszus

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278173597

http://www.w3.org/2001/XMLSchema#string

P698

25014686

http://www.w3.org/2001/XMLSchema#string